和黄医药 (13 HK; 23.75港元; 目标价: 30港元) 呋喹替尼海外销售快速放量,公司有望进入盈利期公司 2024 年收入符合预期,收入增长势头延续。呋喹替尼海外收入高速放量, 国内新适应症持续兑现。赛沃替尼国内销售保持稳定,并有望在今年向 FDA 递交 NDA。索凡替尼启动胰腺癌临床,IIT 研究数据亮眼。血液病管线持续壮大,Syk 抑制剂有望今年国内获批。公司还投入了 ATTC 平台...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.